About lumacaftor + ivacaftor
Cystic fibrosis transmembrane conductance regulator modulator
Used for
- Treats cystic fibrosis in people with two F508del CFTR gene mutations.
Usual adult dose
Adults: lumacaftor 800 mg and ivacaftor 500 mg together every 12 hours with fat-containing food.
Usual dose in children
Children aged 1 year and older: dose is based on age and weight, taken every 12 hours with fat-containing food.
Common side effects
- Cough, headache, or increased mucus
- Nausea or diarrhea
- Raised liver enzymes
- Shortness of breath or chest tightness
Important warnings
- Liver injury can occur; liver tests are monitored.
- Can cause or worsen breathing problems, especially when treatment begins.
- May cause cataracts in children; eye examinations are recommended.
- Can reduce effectiveness of hormonal contraceptives and many other medicines.
Pregnancy
Human pregnancy information is limited; use requires weighing potential benefits and risks.
Breastfeeding
Information is limited; discuss potential infant exposure and treatment benefits with a healthcare professional.
Interactions
- Strong CYP3A inducers, such as rifampin, can reduce treatment effectiveness.
- Strong CYP3A inhibitors, such as ketoconazole, can increase ivacaftor exposure.
- Can reduce hormonal contraceptive effectiveness.
- May affect levels of warfarin, digoxin, and some immunosuppressants.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.